作者
Carla Palleis,Nicolai Franzmeier,Endy Weidinger,Alexander Bernhardt,Sabrina Katzdobler,Stephan Wall,Christian Ferschmann,Stefanie Harris,Julia Schmitt,Sebastian Schuster,Johannes Gnörich,Anika Finze,Gloria Biechele,Simon Lindner,Nathalie L. Albert,Peter Bartenstein,Osama Sabri,Henryk Barthel,Rainer Rupprecht,Brigitte Nuscher,Andrew Stephens,Boris‐Stephan Rauchmann,Robert Perneczky,Christian Haass,Matthias Brendel,Johannes Levin,Günter U. Höglinger
摘要
Corticobasal syndrome (CBS) with underlying 4-repeat tauopathy is a progressive neurodegenerative disease characterized by declining cognitive and motor functions. Biomarkers for assessing pathologic brain changes in CBS including tau-PET, 18 kDa translocator protein (TSPO)-PET, structural MRI, neurofilament light chain (NfL), or glial fibrillary acidic protein (GFAP) have recently been evaluated for differential diagnosis and disease staging, yet their association with disease trajectories remains unclear. Therefore, we performed a head-to-head comparison of neuroimaging (tau-PET, TSPO-PET, structural MRI) and plasma biomarkers (NfL, GFAP) as prognostic tools for longitudinal clinical trajectories in β-amyloid (Aβ)-negative CBS.